MiNK Therapeutics, Inc. (INKT)
NASDAQ: INKT · Real-Time Price · USD
10.22
+0.21 (2.14%)
At close: Nov 11, 2026, 4:00 PM EST
10.22
0.00 (-0.04%)
Pre-market: Nov 12, 2026, 6:35 AM EST
MiNK Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
15
Market Cap
52.17M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Xilio Therapeutics | 55.01M |
| Actinium Pharmaceuticals | 35.09M |
| RenovoRx | 2.78M |
| iBio, Inc. | 1.08M |
| Mereo BioPharma Group | 800.00K |
INKT News
- 23 hours ago - MiNK Therapeutics Earnings Call Transcript: Q3 2026 - Transcripts
- 23 hours ago - MiNK Therapeutics Earnings release: Q3 2026 - Filings
- 23 hours ago - MiNK Therapeutics reports Q3 EPS (50c), consensus (66c) - TheFly
- 1 day ago - MiNK Therapeutics Reports Third Quarter 2026 Results, First Pre-Commercial Product Revenue from agenT-797, Randomized ARDS Trial Advancing, and ARPA-H Selection for Deployable Cell Therapies - GlobeNewsWire
- 5 days ago - MiNK Therapeutics New Data Highlights Its Off-the-Shelf iNKT Cell Therapy Targets Two Key Mechanisms of Tumor Resistance Presented at the Society of Immunotherapy of Cancer (SITC 2026) - GlobeNewsWire
- 8 days ago - MiNK Therapeutics assumed with a Buy at H.C. Wainwright - TheFly
- 9 days ago - MiNK Therapeutics to Report Third Quarter 2026 Results and Outline Progress in Randomized Clinical Development and Scalable iNKT Cell Therapy - GlobeNewsWire
- 22 days ago - MiNK Therapeutics price target raised to $50 from $43 at B. Riley - TheFly